PRESS RELEASE: ABLE Biott Bioreactors now available in Europe
22 August 2019
REPROCELL announce the launch of ABLE Biott Bioreactors in Europe. The lab-scale system will allow researchers to culture stem cells in suspension.
REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders
13 May 2019
REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders.
REPROCELL and Hanugen to custom manufacture clinical grade oligos for gene therapy
24 April 2019
REPROCELL India and Hanugen Therapeutics have announced the launch of their custom manufacture offering for synthesis of milli molar scale clinical grade oligonucleotides for gene therapy.
REPROCELL USA Inc. Achieves Quality Management ISO9001:2015 Certification
08 April 2019
Find out about REPROCELL USA's recently achieved ISO9001:2015 accreditation. demonstrating its ability to consistently meet customer requirements
UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine
14 March 2019
Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, identifying a number of strengths in different industries across the country — including precision medicine innovation in Scotland, led by the University of Glasgow.
REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development
12 March 2019
REPROCELL has joined Medicines Discovery Catapult’s Virtual R&D platform – a unique national network of consultants, private sector CROs, expert labs and public sector centres of excellence, providing medicines discovery expertise, services and virtual programme management.
REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories
28 February 2019
REPROCELL Inc. and Fox Chase, Ltd., have formed a joint venture to begin operations of multi-site biosample repository facilities globally.
Appointment of New Distributor in China
01 February 2019
The REPROCELL group has signed non-exclusive distributorship agreement with RUITAI Biotechnology (Shanghai) Ltd to distribute REPROCELL’s group products in China.
ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production
10 October 2018
Learn more about the partnership between REPROCELL and ROSLINCT aiming to improve efficiency of induced pluripotent stem cell production
REPROCELL announces the launch of a cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: SNIPER
09 October 2018
REPROCELL announced today we have launched a cutting-edge genome editing service utilizing next-generation CRISPR/Cas9 technology, called SNIPER. This service is offered in collaboration with GenAhead Bio Inc. (Kanagawa, Japan).
Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan
01 August 2018
Read the Japan Pharmaceuticals and Medical Device Agency's announcement that REPROCELL has acheived PMDA Approval of CTN for Phase II Trial of Stemchymal
Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services
21 June 2018
Read more about how REPROCELL’s BioServe and Biopta tissue procurement networks have combined to create a new service isolating human primary cells.
REPROCELL’s footprint extends to serve life sciences in India
13 June 2018
Learn more about REPROCELL India's expansion into the life sciences industry through the integration of Oligonucleotide Services and Next Generation Sequencing
Acquisition of BioServe Biotechnologies India Pvt. Ltd.
26 April 2018
REPROCELL announces that it has acquired Bioserve biotechnologies, further expanding REPROCELL's portfolio of service offerings
REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon
18 April 2018
REPROCELL Europe’s CEO, Dr David Bunton, was part of the trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP, 9-13 April 2018.
Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
06 April 2018
Read about REPROCELL's visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017
REPROCELL’s David Bunton addresses the Scottish Parliament
21 March 2018
Discussing how sectors, such as life science, are affected by Scotland’s economic performance and what actions are required to make the economy more inclusive, innovative and international. Topics include key factors in company success, SME’s and government partnership.
Patient-derived tumor organoids recapitulate clinical treatments
14 March 2018
REPROCELL is currently working to develop a highly predictive three-dimensional (3D) human micro-intestine model that can be used to test new drugs for the treatment of IBD and gastrointestinal cancers.
REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018
24 January 2018
Read the announcement that REPROCELL Europe’s CSO Prof Stefan Przyborski will chair the first day of the 3D Cell Culture conference.
Formation of human tissue to improve drug testing and reduce animal research
19 January 2018
REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday.